Marker Therapeutics (MRKR) Competitors

$1.44 -0.02 (-1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.03 (+1.74%)

As of 06:01 PM Eastern

MRKR vs. VRCA, FTLF, BMEA, ANIX, and ONCY

Should you buy Marker Therapeutics stock or one of its competitors? MarketBeat compares Marker Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marker Therapeutics include Verrica Pharmaceuticals (VRCA), FitLife Brands (FTLF), Biomea Fusion (BMEA), Anixa Biosciences (ANIX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Verrica Pharmaceuticals presently has a consensus price target of $14.50, suggesting a potential upside of 144.52%. Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 594.44%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Marker Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.86	-$17.89M	-$1.03	N/A
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A

In the previous week, Marker Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Marker Therapeutics and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Marker Therapeutics' score of 1.44 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Very Positive
Marker Therapeutics	Positive

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Verrica Pharmaceuticals and Marker Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

FitLife Brands has a net margin of 6.64% compared to Marker Therapeutics' net margin of -343.03%. FitLife Brands' return on equity of 18.31% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

FitLife Brands has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, FitLife Brands had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for FitLife Brands and 2 mentions for Marker Therapeutics. FitLife Brands' average media sentiment score of 1.60 beat Marker Therapeutics' score of 1.44 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Overall Sentiment
FitLife Brands	Very Positive
Marker Therapeutics	Positive

2.3% of FitLife Brands shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 61.7% of FitLife Brands shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

FitLife Brands currently has a consensus target price of $21.50, suggesting a potential upside of 93.52%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 594.44%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

FitLife Brands has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.28	$6.33M	$0.60	18.52
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A

Summary

FitLife Brands beats Marker Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to Biomea Fusion?

Marker Therapeutics (NASDAQ:MRKR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Biomea Fusion has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Biomea Fusion	N/A	-265.37%	-103.96%

In the previous week, Biomea Fusion had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.44 beat Biomea Fusion's score of 0.80 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Positive
Biomea Fusion	Positive

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 594.44%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 558.91%. Given Marker Therapeutics' higher probable upside, equities analysts plainly believe Marker Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Marker Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Marker Therapeutics has higher revenue and earnings than Biomea Fusion. Marker Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

Marker Therapeutics beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Anixa Biosciences?

Marker Therapeutics (NASDAQ:MRKR) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Anixa Biosciences has lower revenue, but higher earnings than Marker Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A
Anixa Biosciences	$210K	516.78	-$10.93M	-$0.31	N/A

Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Anixa Biosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Anixa Biosciences' return on equity of -71.12% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Anixa Biosciences	N/A	-71.12%	-62.88%

In the previous week, Anixa Biosciences had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 5 mentions for Anixa Biosciences and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.44 beat Anixa Biosciences' score of 0.57 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Positive
Anixa Biosciences	Positive

Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 594.44%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 166.46%. Given Marker Therapeutics' higher possible upside, equities research analysts clearly believe Marker Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Anixa Biosciences beats Marker Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Marker Therapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A

Oncolytics Biotech has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

In the previous week, Oncolytics Biotech had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Oncolytics Biotech and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.44 beat Oncolytics Biotech's score of 1.16 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
Marker Therapeutics	Positive

Oncolytics Biotech currently has a consensus target price of $8.50, suggesting a potential upside of 835.92%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 594.44%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Oncolytics Biotech is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Oncolytics Biotech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Marker Therapeutics beats Oncolytics Biotech on 9 of the 15 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.34M	$3.02B	$6.85B	$12.45B
Dividend Yield	N/A	2.08%	2.68%	8.43%
P/E Ratio	-2.36	18.77	27.04	24.38
Price / Sales	6.76	344.35	524.25	93.51
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	1.43	4.20	10.80	6.33
Net Income	-$12.16M	$65.13M	$3.59B	$331.02M
7 Day Performance	-14.29%	-3.41%	-2.24%	-1.09%
1 Month Performance	4.35%	2.41%	3.12%	-0.49%
1 Year Performance	-8.86%	20.10%	26.30%	19.90%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	3.2201 of 5 stars	$1.44 -1.4%	$10.00 +594.4%	-14.6%	$24.34M	$3.55M	N/A	60	Positive News Short Interest Decrease
VRCA Verrica Pharmaceuticals	3.2355 of 5 stars	$6.25 +2.0%	$14.50 +132.0%	-26.6%	$107.38M	$35.58M	N/A	40	Positive News
FTLF FitLife Brands	4.6254 of 5 stars	$11.07 -1.1%	$21.50 +94.3%	-14.1%	$104.83M	$81.46M	18.48	20	News Coverage Positive News Short Interest Decrease
BMEA Biomea Fusion	2.4503 of 5 stars	$1.42 +2.5%	$8.50 +500.7%	-33.5%	$102.30M	N/A	N/A	50	News Coverage
ANIX Anixa Biosciences	4.0864 of 5 stars	$3.00 -1.6%	$8.50 +183.3%	-2.5%	$102.06M	$210K	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. VRCA, FTLF, BMEA, ANIX, and ONCY

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Marker Therapeutics compare to FitLife Brands?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Summary

How does Marker Therapeutics compare to Anixa Biosciences?

Summary

How does Marker Therapeutics compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. VRCA, FTLF, BMEA, ANIX, and ONCY

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Do analysts recommend VRCA or MRKR?

Which has more volatility and risk, VRCA or MRKR?

Is VRCA or MRKR more profitable?

Which has stronger earnings and valuation, VRCA or MRKR?

Does the media favor VRCA or MRKR?

Do institutionals & insiders hold more shares of VRCA or MRKR?

Summary

How does Marker Therapeutics compare to FitLife Brands?

Is FTLF or MRKR more profitable?

Which has more volatility & risk, FTLF or MRKR?

Does the media favor FTLF or MRKR?

Do insiders & institutionals hold more shares of FTLF or MRKR?

Do analysts rate FTLF or MRKR?

Which has preferable valuation and earnings, FTLF or MRKR?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Is MRKR or BMEA more profitable?

Does the media refer more to MRKR or BMEA?

Do insiders and institutionals believe in MRKR or BMEA?

Do analysts rate MRKR or BMEA?

Which has more volatility and risk, MRKR or BMEA?

Which has stronger valuation and earnings, MRKR or BMEA?

Summary

How does Marker Therapeutics compare to Anixa Biosciences?

Which has higher valuation and earnings, MRKR or ANIX?

Which has more risk & volatility, MRKR or ANIX?

Is MRKR or ANIX more profitable?

Does the media favor MRKR or ANIX?

Do analysts prefer MRKR or ANIX?

Do institutionals and insiders believe in MRKR or ANIX?

Summary

How does Marker Therapeutics compare to Oncolytics Biotech?

Which has higher earnings & valuation, ONCY or MRKR?

Is ONCY or MRKR more profitable?

Does the media favor ONCY or MRKR?

Do analysts rate ONCY or MRKR?

Which has more risk & volatility, ONCY or MRKR?

Do insiders & institutionals have more ownership in ONCY or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools